Delving into the Latest Updates on Phynova Group Ltd. with Synapse

A twelve-week randomised, placebo-controlled study on the effect of Reducose® on glucose, insulin, haemoglobin A1c, satiety, body composition, lipid profile, inflammatory markers and changes in gut microbiome in an overweight population. REMET (Reducose Metabolic Trial)

开始日期2024-10-28

申办/合作机构

Phynova Group Ltd.

[+1]

ISRCTN18212231 / CompletedN/A

A double-blind, placebo-controlled, four-arm, single-dose, cross over, dose-ranging trial to investigate the effects of Reducose mulberry leaf extract on postprandial glucose and insulin after consuming a complex meal

开始日期2020-01-03

申办/合作机构

Phynova Group Ltd.

ISRCTN99601810 / CompletedN/A

Clinical stUdy to assess the Glycaemic Effect of Reducose on a Sucrose challenge (SUGERS): a double blind, placebo controlled, crossover study

开始日期2016-03-21

申办/合作机构

Phynova Group Ltd.

100 项与 Phynova Group Ltd. 相关的临床结果

登录后查看更多信息

0 项与 Phynova Group Ltd. 相关的专利（医药）

登录后查看更多信息

5

项与 Phynova Group Ltd. 相关的文献（医药）

2021-12-01·Nutrition & Metabolism

Correction to: Mulberry leaf extract improves glycaemic response and insulaemic response to sucrose in healthy subjects: results of a randomized, double blind, placebo‑controlled study

作者: Ahlstrom, Lis ; Thondre, Pariyarath Sangeetha ; Gallagher, Andrew ; Lightowler, Helen

An amendment to this paper has been published and can be accessed via the original article.

2021-12-01·Nutrition & Metabolism3区 · 医学

Mulberry leaf extract improves glycaemic response and insulaemic response to sucrose in healthy subjects: results of a randomized, double blind, placebo-controlled study

3区 · 医学

ArticleOA

作者: Ahlstrom, Lis ; Thondre, Pariyarath Sangeetha ; Gallagher, Andrew ; Lightowler, Helen

AbstractBackgroundThere are many benefits of maintaining healthy blood glucose levels, and studies have shown that lifestyle changes such as changes to diet can successfully restore normoglycaemia in participants with dysglycaemia. Significant health-related lifestyle changes are often difficult to implement and functional ingredients that can reduce glycaemic and insulaemic responses may help at risk populations. The aim of this study was to investigate whether a mulberry leaf extract could lower the glycaemic and insulinaemic responses to 75 g sucrose in healthy individuals.MethodsA double-blind, randomised, placebo-controlled, crossover design trial was conducted by the Oxford Brookes Centre for Nutrition and Health. Thirty-eight participants were recruited into the trial and, after an overnight fast, were given 75 g sucrose + white mulberry leaf extract, or 75 g sucrose alone. Capillary blood samples were collected at 15-min intervals in the first hour and at 30-min intervals over the second hour to determine glucose and plasma insulin levels. Data analysis was conducted using a paired samples T test or a Wilcoxon signed rank test.ResultsThe addition of mulberry leaf extract to sucrose resulted in a significantly lower glycaemic response and insulinaemic response compared to a matched placebo (sucrose alone). The change in blood glucose measurements were significantly lower at 15 min (p < 0.001), 30 min (p < 0.001), 45 min (p = 0.008), and 120 min (p < 0.001) and plasma insulin measurements were significantly lower at 15 min (p < 0.001), 30 min (p < 0.001), 45 min (p < 0.001), 60 min (p = 0.001) and 120 min (p < 0.001). The glucose iAUC (− 42%, p = 0.001), insulin iAUC (− 40%, p < 0.001), peak glucose (− 40.0%, p < 0.001) and peak insulin (− 41%, p < 0.001) from baseline were significantly lower for white mulberry leaf extract compared with the placebo. White mulberry leaf extract was well tolerated and there were no reported adverse events.ConclusionsMulberry leaf extract can be used as part of lifestyle changes that may lead to healthy blood glucose levels.Trial registration: ISRCTN99601810 (23 October 2020, retrospectively registered)

2015-12-01·Trials4区 · 医学

Mulberry extract to modULate Blood glucosE Responses in noRmoglYcaemic adults (MULBERRY): study protocol for a randomised controlled trial

4区 · 医学

ArticleOA

作者: Lightowler, Helen ; Gallagher, Andrew ; Lown, Mark ; Stuart, Beth ; Fuller, Richard ; Byrne, Christopher D ; Lewith, George ; Fraser, Ann

BACKGROUNDWorldwide sugar consumption has tripled during the last fifty years. High sugar intake is associated with weight gain and increased incidence of diabetes and has been linked with increased cardiovascular mortality. Reducing the health impact of dietary sugar and poor quality carbohydrate intake is a public health priority. IminoNorm®, a proprietary mulberry leaf extract (ME), may reduce blood glucose responses following dietary sugar and carbohydrate intake by reducing absorption of glucose from the gut. Previous research has shown that ME can reduce blood glucose and improve insulin responses in healthy subjects and also in subjects with raised fasting blood glucose levels. Mulberry leaf has an excellent safety profile. This pilot study will test a novel, safe, water soluble product in normoglycaemic adults in the UK to determine if it can reduce glucose absorption without increasing plasma insulin concentration.METHODS/DESIGNThe trial will be a double-blind, individually randomised, four-arm single-dose crossover design to test the effect of three doses of ME in order to determine efficacy, dose response relationship and gastrointestinal side effects with respect to placebo. A total of 40 subjects will participate in this study and attend for four visits receiving each of the four interventions in random order.DISCUSSIONWe aim to test the evidence that mulberry leaf extract can reduce blood glucose without a disproportionate increase in blood insulin responses in healthy individuals in a high-quality research study based in the UK. It is hoped that this will lead to further randomised controlled trials and an effective dietary supplement to lower blood glucose concentrations.TRIAL REGISTRATIONISRCTNISRCTN14597438 (21 April 2015).

100 项与 Phynova Group Ltd. 相关的药物交易

登录后查看更多信息

100 项与 Phynova Group Ltd. 相关的转化医学

登录后查看更多信息

组织架构

使用我们的机构树数据加速您的研究。

登录

或

查看完整样例数据

管线布局

2024年11月18日管线快照

管线布局中药物为当前组织机构及其子机构作为药物机构进行统计，早期临床1期并入临床1期，临床1/2期并入临床2期，临床2/3期并入临床3期

临床前

2

12

其他

登录后查看更多信息

当前项目

药物(靶点)	适应症	全球最高研发状态

BCL-5 ( Glycosidases )	2型糖尿病更多	临床前
PYN-18	丙型肝炎更多	临床前
Altirex	丙型肝炎更多	终止
PYN-6	细菌感染更多	无进展
PYN-9	肠阻塞更多	无进展